300. Risk factors for the development of active Methicillin-resistant Staphylococcus aureus (MRSA) infection in patients colonized with MRSA at hospital admission.
Session: Poster Abstract Session: HAI: MSSA, MRSA, and other Gram-Positives
Thursday, October 27, 2016
Room: Poster Hall
Background: Patients who present to VA hospitals are screened for methicillin resistant Staphylococcus aureus (MRSA) colonization. Those who test positive are isolated during their hospital stay. However, it is unknown which of these patients are most likely to subsequently develop active MRSA infections.

Methods: Our retrospective-case-control study characterized risk factors for active MRSA infection among patients colonized with MRSA during acute care hospital admission. Potential demographic and clinical risk factors were identified using electronic queries and manual chart abstraction; data were compared by standard statistical tests and variables with P values < 0.05 in bivariable analysis were entered into a multivariable logistic regression model.

Results: There were 71 cases and 213 controls. Risk factors associated with MRSA infection included diabetes mellitus with or without end organ damage (26% vs. 14%, p=0.02), hemiplegia (9% vs. 2%, p=0.01), chronic kidney disease (33% vs. 20%, p=0.03), post-colonization inpatient admission within 90 days (44% vs 29%, p=0.03), surgery (41% vs. 9%, p<0.01), and dialysis (10% vs. 3%, p=0.02). On multivariable analysis, surgery during follow-up, dialysis during follow-up, and hemiplegia remained significant.

Conclusion: Among patients with MRSA colonization, surgery or dialysis during follow-up, and history of hemiplegia, were associated with subsequent MRSA infection. Knowledge of these risk factors might enable future targeted interventions to prevent MRSA infections among colonized patients.

Jose Cadena, MD/ID, University of Texas Health Sciencer at San Antonio, San Antonio, TX; South Texas Veterans Healthcare System, San Antonio, TX, Elizabeth Walter, MD, Medicine/Infectious Diseases, University of Texas Health Science Center at San Antonio and South Texas Veterans Health Care System, San Antonio, TX, Christopher R. Frei, PharmD, MSc, The University of Texas at Austin, San Antonio, TX; University of Texas Health Science Center, San Antonio, TX and Josephine Thinwa, MD/ PhD, Medicine, UTHSCSA, San Antonio, TX

Disclosures:

J. Cadena, None

E. Walter, None

C. R. Frei, Bristol Myers Squibb: Grant Investigator , Research grant
Forest: Grant Investigator , Research grant
Pfizer: Grant Investigator , Research grant
Pharmacyclics: Grant Investigator , Research grant

J. Thinwa, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.